Article in Annals of clinical and translational neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Stephanie B Syc-MazurekDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-9549-6648
Ji Yeon HanDepartment of Pediatrics, Inha University Hospital, Incheon, Republic of Korea.ORCID 0000-0001-8671-5215
Jun-Soon KimDepartment of Neurology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.ORCID 0000-0001-7685-2793
Kyomin ChoiDepartment of Neurology, Soonchunhyang University Cheonan Hospital, Cheonan, Republic of Korea.ORCID 0000-0001-9730-3363
Seong-Il OhDepartment of Neurology, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, Republic of Korea.ORCID 0000-0002-8067-2135
Seok-Jin ChoiDepartment of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.ORCID 0000-0001-6444-977X
Eunhee SohnDepartment of Neurology, Chungnam National University College of Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea.ORCID 0000-0001-5610-7606
Jeeyoung OhDepartment of Neurology, Konkuk University School of Medicine, Konkuk University Medical Center, Seoul, Republic of Korea.ORCID 0000-0002-0378-2947
Seung Woo KimDepartment of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.ORCID 0000-0002-5621-0811
Ha Young ShinDepartment of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.ORCID 0000-0002-4408-8265
Byung Chan LimDepartment of Pediatrics, Seoul National University College of Medicine, Seoul National University Children's Hospital, Seoul, Republic of Korea.ORCID 0000-0002-8509-4135
Byoung Joon KimDepartment of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Kyung Seok ParkDepartment of Neurology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
Jung-Joon SungDepartment of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.ORCID 0000-0001-7525-5313
Se Hoon KimDepartment of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Sung-Hye ParkDepartment of Pathology, Seoul National University Hospital, Seoul National University, College of Medicine, Seoul, Republic of Korea.ORCID 0000-0002-8681-1597
Anastasia ZekeridouDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-1960-9065
Claudia F LucchinettiDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-5070-1196
Sean J PittockDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-6140-5584
John J ChenDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0003-3644-7528
Eoin P FlanaganDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Sung-Min KimDepartment of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
Funding
Utilizing epidemiology, imaging and fluid biomarkers in MOG antibody-associated disease to inform prognosis, pathogenesis and therapeuticsR01NS113828 · NINDS · MAYO CLINIC ROCHESTER · PI Eoin P Flanagan · 2020 to 2026
$2.4M
National Research Foundation of Korea 2020R1C1C1012255NINDS NIH HHS R01 NS113828NINDS NIH HHS R01NS113828
6 · The paper itself
Abstract
Cases of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) co-occurring with neoplasms have been reported. In this international, retrospective cohort study in South Korea and the USA, 16 of 445 (3.6%) patients with MOGAD had concurrent neoplasm within 2 years of MOGAD onset, resulting in a standardized incidence ratio for neoplasm of 3.10 (95% confidence interval [CI], 1.77-4.81; P < 0.001) when compared to the age- and country-adjusted incidence of neoplasm in the general population. However, none of the nine tumor tissues obtained demonstrated MOG immunostaining. The slightly increased frequency without immunohistopathological evidence suggest with true paraneoplastic MOGAD is extremely rare.
Indexed as
Demyelinating Autoimmune Diseases, CNSMyelin-Oligodendrocyte GlycoproteinNeoplasmsAdultAgedAged, 80 and overAutoantibodiesFemaleHumansIncidenceMaleMiddle AgedMyelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseRepublic of KoreaRetrospective StudiesUnited StatesAutoantibodiesMyelin-Oligodendrocyte Glycoprotein
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Assessment of concurrent neoplasms and a paraneoplastic association in MOGAD. · full record | OpenQuestion